Given the fact that the loss of ARID2 makes melanoma cells more sensitive to immunotherapies, it is now necessary to investigate the role of ARID2 as a biomarker predicting HCC response to immunotherapy. Here, ARID2 is linked to hepatocellular carcinoma.